tbuckley/cabot-search huggingface dataset:
Low-Dose Aspirin for the Prevention of Preeclampsia
Authors: Jimmy Espinoza
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
Authors: Z. Andric, T. Ceric, M. Rancic, M. Jakopovic, S. Ponce Aix, R. Ramlau, M. Ulanska, C. Caldwell, D. Ferrari, A. Annis, V. Vukovic, B. Zaric
Journal: Annals of Oncology (2021)
Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study
Authors: Dan Lewer, Brian Eastwood, Martin White, Thomas D. Brothers, Martin McCusker, Caroline Copeland, Michael Farrell, Irene Petersen
Journal: PLoS Medicine (2021)

Hospital patients who use illicit opioids such as heroin may use drugs during an admission or leave the hospital in order to use drugs. There have been reports of patients found dead from drug poisoning on the hospital premises or shortly after leaving the hospital. This study examines whether hospital admission and discharge are associated with increased risk of opioid-related death.We conducted a case-crossover study of opioid-related deaths in England. Our study included 13,609 deaths between January 1, 2010 and December 31, 2019 among individuals aged 18 to 64. For each death, we sampled 5 control days from the period 730 to 28 days before death. We used data from the national Hospital Episode Statistics database to determine the time proximity of deaths and control days to hospital admissions. We estimated the association between hospital admission and opioid-related death using conditional logistic regression, with a reference category of time neither admitted to the hospital nor within 14 days of discharge. A total of 236/13,609 deaths (1.7%) occurred following drug use while admitted to the hospital. The risk during hospital admissions was similar or lower than periods neither admitted to the hospital nor recently discharged, with odds ratios 1.03 (95% CI 0.87 to 1.21; p = 0.75) for the first 14 days of an admission and 0.41 (95% CI 0.30 to 0.56; p < 0.001) for days 15 onwards. 1,088/13,609 deaths (8.0%) occurred in the 14 days after discharge. The risk of opioid-related death increased in this period, with odds ratios of 4.39 (95% CI 3.75 to 5.14; p < 0.001) on days 1 to 2 after discharge and 2.09 (95% CI 1.92 to 2.28; p < 0.001) on days 3 to 14. 11,629/13,609 deaths (85.5%) did not occur close to a hospital admission, and the remaining 656/13,609 deaths (4.8%) occurred in hospital following admission due to drug poisoning. Risk was greater for patients discharged from psychiatric admissions, those who left the hospital against medical advice, and those leaving the hospital after admissions of 7 days or more. The main limitation of the method is that it does not control for time-varying health or drug use within individuals; therefore, hospital admissions coinciding with high-risk periods may in part explain the results.Discharge from the hospital is associated with an acute increase in the risk of opioid-related death, and 1 in 14 opioid-related deaths in England happens in the 2 weeks after the hospital discharge. This supports interventions that prevent early discharge and improve linkage with community drug treatment and harm reduction services.
1823P Differential mutational landscape of duodenal carcinomas: A real-world data analysis from the GENIE Consortium Cohort
Authors: I. Fernandes, R. Franco, V. Franco, R. Carmagnani Pestana, D. Bugano Diniz Gomes, D.F. Saragiotto, A.I.C. Leal
Journal: Annals of Oncology (2021)
The Pursuit and Maintenance of Happiness
Authors: Jeffrey L. Jackson
Journal: New England Journal of Medicine (2021)

Happiness was articulated as a fundamental right by the founding fathers of the United States. Few illnesses interfere with the pursuit of happiness more than depression, and approximately 6% of the world's population is depressed at any given time. Depression is commonly encountered in primary care, with up to one third of patients having depressive symptoms and 10% meeting criteria for major depression.1 Depressed patients typically report physical rather than emotional symptoms and as a result are often referred to specialty clinics, in which the frequency of undiagnosed depression among new patients may be even higher than that in primary . . .
Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019
Authors: Jason M. Nagata, Adrienne Epstein, Kyle T. Ganson, Tarik Benmarhnia, Sheri D. Weiser
Journal: PLoS Medicine (2021)

Background Extreme weather events, including droughts, are expected to increase in parts of sub-Saharan Africa and are associated with a number of poor health outcomes; however, to the best of our knowledge, the link between drought and childhood vaccination remains unknown. The objective of this study was to evaluate the relationship between drought and vaccination coverage. Methods and findings We investigated the association between drought and vaccination coverage using a retrospective analysis of Demographic and Health Surveys data in 22 sub-Saharan African countries among 137,379 children (50.4% male) born from 2011 to 2019. Drought was defined as an established binary variable of annual rainfall less than or equal to the 15th percentile relative to the 29 previous years, using data from Climate Hazards Group InfraRed Precipitation with Station (CHIRPS) data. We evaluated the association between drought at the date of birth and receipt of bacillus Calmette–Guérin (BCG), diphtheria–pertussis–tetanus (DPT), and polio vaccinations, and the association between drought at 12 months of age and receipt of measles vaccination. We specified logistic regression models with survey fixed effects and standard errors clustered at the enumeration area level, adjusting for child-, mother-, and household-level covariates and estimated marginal risk differences (RDs). The prevalence of drought at date of birth in the sample was 11.8%. Vaccination rates for each vaccination ranged from 70.6% (for 3 doses of the polio vaccine) to 86.0% (for BCG vaccination); however, only 57.6% of children 12 months and older received all recommended doses of BCG, DPT, polio, and measles vaccinations. In adjusted models, drought at date of birth was negatively associated with BCG vaccination (marginal RD = −1.5; 95% CI −2.2, −0.9), DPT vaccination (marginal RD = −1.4; 95% CI −2.2, −0.5), and polio vaccination (marginal RD = −1.3; 95% CI −2.3, −0.3). Drought at 12 months was negatively associated with measles vaccination (marginal RD = −1.9; 95% CI −2.8, −0.9). We found a dose–response relationship between drought and DPT and polio vaccinations, with the strongest associations closest to the timing of drought. Limitations include some heterogeneity in findings across countries. Conclusions In this study, we observed that drought was associated with lower odds of completion of childhood BCG, DPT, and polio vaccinations. These findings indicate that drought may hinder vaccination coverage, one of the most important interventions to prevent infections among children. This work adds to a growing body of literature suggesting that health programs should consider impacts of severe weather in their programming.
651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Authors: S. Sadeghi, D.I. Quinn, T. Dorff, S.K. Pal, S. Groshen, D. Tsao-Wei, P.N. Lara, R. Parikh, M.E. Devitt, M. Parikh, A. Jackovich, N.J. Vogelzang, E.F. Burgess, R. Dreicer, I. Siddiqi, I. Gill, P. Gill
Journal: Annals of Oncology (2021)
1777P HEME catabolism in peripheral monocytes and response to immune checkpoint inhibitors in advanced lung cancer
Authors: F. Biello, V. Martini, C. Branni, G. Borra, S. Genestroni, A. Mennitto, C. Cattrini, A.P. Sponghini, A. Gatti, F. Platini, A. Rua, P.M. Maggiora, M. Cavalleri, A.R. Vachanaram, F.M. Varughese, D. Ferrante, D.J. Pinato, A. Sica, A. Gennari
Journal: Annals of Oncology (2021)
1268P Real-time clinical utility of ctDNA genomic alterations in untreated patients with advanced NSCLC
Authors: M. Garcia De Herreros, S. Muñoz, C. Teixido, V. Díez-Guardia, A. Arcocha, C. Pipinikas, D. Martínez, S. Castillo, R. Reyes, M. Riudavets Melia, E. Auclin, E. Marin, K. Howarth, D. Martinez, J.A. Puig, A. Prat, N. Reguart Aransay, N. Viñolas, L. Mezquita
Journal: Annals of Oncology (2021)
Injectable and conductive cardiac patches repair infarcted myocardium in rats and minipigs
Authors: Leyu Wang, Yuqing Liu, Genlan Ye, Yutong He, Bingyun Li, Yezhi Guan, Baoyong Gong, Kibret Mequanint, Malcolm M. Q. Xing, Xiaozhong Qiu
Journal: Nature Biomedical Engineering (2021)
LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
Authors: H. Kenmotsu, K. Wakuda, K. Mori, T. Kato, S. Sugawara, K. Kirita, I. Okamoto, K. Azuma, K. Nishino, S. Teraoka, R. Koyama, K. Masuda, H. Hayashi, R. Toyozawa, S. Miura, Y. Sato, K. Nakagawa, N. Yamamoto, T. Takahashi
Journal: Annals of Oncology (2021)
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
Authors: Maulasri Bhatta, Gautam N Shenoy, Jenni L Loyall, Brian D Gray, Meghana Bapardekar, Alexis Conway, Hans Minderman, Raymond J Kelleher Jr, Beatriz M Carreno, Gerald Linette, Leonard D Shultz, Kunle Odunsi, Sathy V Balu-Iyer, Koon Yan Pak, Richard B Bankert
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background The human tumor microenvironment (TME) is a complex and dynamic milieu of diverse acellular and cellular components, creating an immunosuppressive environment, which contributes to tumor progression. We have previously shown that phosphatidylserine (PS) expressed on the surface of exosomes isolated from human TMEs is causally linked to T-cell immunosuppression, representing a potential immunotherapeutic target. In this study, we investigated the effect of ExoBlock, a novel PS-binding molecule, on T-cell responses in the TME. Methods We designed and synthesized a new compound, (ZnDPA) 6 -DP-15K, a multivalent PS binder named ExoBlock. The PS-binding avidity of ExoBlock was tested using an in vitro competition assay. The ability of this molecule to reverse exosome-mediated immunosuppression in vitro was tested using human T-cell activation assays. The in vivo therapeutic efficacy of ExoBlock was then tested in two different human tumor xenograft models, the melanoma-based xenomimetic (X-)mouse model, and the ovarian tumor-based omental tumor xenograft (OTX) model. Results ExoBlock was able to bind PS with high avidity and was found to consistently and significantly block the immunosuppressive activity of human ovarian tumor and melanoma-associated exosomes in vitro. ExoBlock was also able to significantly enhance T cell-mediated tumor suppression in vivo in both the X-mouse and the OTX model. In the X-mouse model, ExoBlock suppressed tumor recurrence in a T cell-dependent manner. In the OTX model, ExoBlock treatment resulted in an increase in the number as well as function of CD4 and CD8 T cells in the TME, which was associated with a reduction in tumor burden and metastasis, as well as in the number of circulating PS+ exosomes in tumor-bearing mice. Conclusion Our results establish that targeting exosomal PS in TMEs with ExoBlock represents a promising strategy to enhance antitumor T-cell responses.
1812P Clinical and pathological features and prognosis of non-small cell lung cancer (NSCLC) patients with adenocarcinomas without TTF1 and Napsin A expression
Authors: F. Kraus, G. Nilius, S. Bölükbas, I. Stöver, A. Koziorowski, F. Grabellus, D.C. Christoph
Journal: Annals of Oncology (2021)
CN54 Impact of the app-based and nurse-led supportive care program AKO@dom on dose-intensity of oral targeted therapies in patients with metastatic renal cell cancer: A multicentric observational retrospective study
Authors: V. Gaillard, A. Lhuillier, C. Bigot, L. Pierard, P. Trensz, C. Schuster, G. Malouf, A. Fritsch, D. Borchiellini, L. Geoffrois, P. Barthelemy
Journal: Annals of Oncology (2021)
Prognostic Value of FDG PET/CT in Patients With Neuroendocrine Carcinoma of the Uterine Cervix
Authors: Yuanyuan Jiang, Guozhu Hou, Fang Li, Zhaohui Zhu, Wuying Cheng
Journal: Clinical Nuclear Medicine (2021)

Purpose We evaluated the prognostic value of metabolic parameters measured on pretreatment FDG PET/CT in patients with cervical neuroendocrine carcinomas (NECs). Methods A total of 22 patients with cervical NECs who underwent pretreatment FDG PET/CT were retrospectively reviewed. The SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary lesion were measured. The associations between prognostic factors and progression-free survival (PFS) and overall survival (OS) were investigated using the Kaplan-Meier method, log-rank test, and univariate and multivariate Cox proportional hazards model. Results Of the 22 patients, 12 developed disease progression, and 5 died during the follow-up period. Univariate analyses revealed that MTV, TLG, and the International Federation of Gynecology and Obstetrics stage were significantly associated with PFS (all P &lt; 0.05), whereas SUVmax did not show a significant correlation with PFS. Kaplan-Meier survival curves revealed that patients with MTV &gt;31.9 cm 3 (log-rank, P &lt; 0.001), TLG &gt;154.3 (log-rank, P &lt; 0.001), and higher International Federation of Gynecology and Obstetrics stage (log-rank, P = 0.026) had significantly shorter PFS. In the multivariate analyses, MTV ( P = 0.017; hazard ratio [HR], 7.298; 95% confidence interval [CI], 1.427–37.316) and TLG ( P = 0.003; HR, 15.175; 95% CI, 2.470–93.244) were independent prognostic factors, whereas for OS, the univariate analysis revealed that only TLG &gt;154.3 showed statistical significance ( P = 0.043; HR, 9.821; 95% CI, 1.080–89.290). Conclusions Metabolic tumor volume and TLG on FDG PET/CT were the significant prognostic factors of PFS in patients with cervical NECs. Patients with high MTV and TLG had worse clinical outcomes. In addition, TLG may also be a predictor of OS.
897P Genomic alterations in smokers with oropharyngeal squamous cell cancer (OSCC) determined by targeted next generation sequencing
Authors: P. Economopoulou, M. Anastasiou, A. Spathis, A. Pantazopoulos, I. Kotsantis, N. Gavrielatou, M. Prevezanou, I. Chatzidakis, G. Kavourakis, A. Kyriazoglou, A. Psyrri
Journal: Annals of Oncology (2021)
Early-Life Initiation of Primary Prevention Strategies to Reduce Atherosclerosis Risk—Reply
Authors: Matthew K. Armstrong, Brooklyn J. Fraser, Costan G. Magnussen
Journal: JAMA Cardiology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
1331P Open-label phase I/II study evaluating the tolerability and anti-tumor activity of selinexor (SEL) and docetaxel (DTX) in non-small cell lung cancer (NSCLC)
Authors: A. Zer, J. Dudnik, S. Shamai, M. Gottfried, A. Zick, A. Shai, T. Shentzer Kutiel, E. Netiv, F. Yang, S. Sharoni, C. Meng, P. Duic, D. Michel, E. Sbar, J. Shah, M.G. Kauffman, S. Shacham, T. Golan
Journal: Annals of Oncology (2021)
225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer
Authors: Yasemin Sanli, Serkan Kuyumcu, Duygu Has Simsek, Fikret Büyükkaya, Caner Civan, Emine Goknur Isik, Zeynep Gozde Ozkan, Mert Basaran, Oner Sanli
Journal: Clinical Nuclear Medicine (2021)

Purpose Prostate-specific membrane antigen (PSMA)–targeted therapies are among the current promising treatments. We present our preliminary results on the use of 225 Ac-PSMA therapy in patients with metastatic castration-resistant prostate cancer as a single center. Methods Twelve advanced stage metastatic castration-resistant prostate cancer patients who received 225 Ac-PSMA therapy were recruited in this retrospective study. Patients were treated with 225 Ac-PSMA therapy every 8 weeks, and prostate-specific antigen (PSA) response was analyzed. Meanwhile, overall survival (OS) and progression-free survival (PFS) were estimated. Hematological and nonhematological adverse effects were recorded before and at 8 weeks after the last treatment cycle. Results In total, 25 cycles of 225 Ac-PSMA were administered to 12 patients. The pretreatment median PSA level was 129 ng/mL. After the first cycle of therapy, any PSA response was observed in 9 of 12 patients, whereas 6 of them had biochemical response of &gt;50%. Four of 12 patients reached the best PSA response after the first treatment cycle, whereas 3 patients after the second and 2 patients after the third cycle. The median PFS and OS were 4 and 10 months, respectively. For patients with any PSA response after the first cycle, OS was found to be higher despite without any statistical significance (10 vs 4 months; P = 0.301) when compared with the nonresponsive group. No significant difference was encountered in terms of adverse effect in the pretreatment and posttreatment era. Conclusions Our preliminary results are encouraging, especially patients who had PSA response after the first cycle of 225 Ac-PSMA therapy.
1097O The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
Authors: R. Garcia-Carbonero, M. Benavent, P. Jiménez Fonseca, D. Castellano, T. Alonso-Gordoa, A. Teulé, A. Custodio, S. Tafuto, A. La Casta, F. Spada, C. López, T. Ibrahim, M.J. Villanueva Silva, V. Iranzo, P. García-Alfonso, E. González-Flores, E. Grande, G. Crespo, A. Carmona-Bayonas, J. Capdevila
Journal: Annals of Oncology (2021)
490P New horizons in metastatic colorectal cancer: Role of CD44 expression
Authors: P. Ziranu, V. Aimola, A. Pretta, G. Cerrone, M. Persano, N. Liscia, M. Dubois, M. Migliari, F. Sarais, E. Cimbro, A. Parrino, D. Spanu, S. Mariani, C. Donisi, G. Pinna, V. Pusceddu, M. Puzzoni, E. Lai, G. Faa, M. Scartozzi
Journal: Annals of Oncology (2021)
343MO Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma
Authors: M.J. Mair, E. Tomasich, G. Heller, L. Müller, A. Wöhrer, B. Kiesel, G. Widhalm, K. Dieckmann, J.A. Hainfellner, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2021)
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Authors: T.A. Leal, D. Berz, I. Rybkin, W.T. Iams, D. Bruno, C. Blakely, A. Spira, M.R. Patel, D.M. Waterhouse, D. Richards, A. Pham, R. Jotte, E.B. Garon, D. Hong, R. Shazer, X. Yan, L. Latven, K. He
Journal: Annals of Oncology (2021)
660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
Authors: T.K. Choueiri, M. Eto, E. Kopyltsov, S.Y. Rha, C.G. Porta, R. Motzer, V. Grünwald, T.E. Hutson, M.J. Méndez-Vidal, S-H. Hong, E. Winquist, J.C.H. Goh, P. Maroto, T. Buchler, T. Takagi, K. Rodriguez-Lopez, D. Xing, A.D. Smith, T. Powles
Journal: Annals of Oncology (2021)
Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports Elisabeth MahaseThe antiviral drug molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised adults who had mild to moderate covid-19 and were at risk of poor outcomes, Merck Sharp and Dohme (MSD) has reported.
406P The analysis of driver mutations in paired samples of rectal carcinomas obtained before and after neoadjuvant chemoradiotherapy
Authors: E.N. Imyanitov, S. Aleksakhina, A. Martianov, D. Kuzovenkova, D. Samsonov, O. Ivko, A.M. Karachun
Journal: Annals of Oncology (2021)
心室再同期療法(CRT)により先天性心疾患(CHD)術後心不全の劇的な改善を得た1例
Authors: 大橋直樹, 松島正氣, 西川浩, 久保田勤也, 櫻井一, 水谷真一, 加藤紀之, 澤木完成, 櫻井寛久, 杉浦純也, 福見大地
Journal: Circulation (2006)
心臓手術後の神経心理学的機能不全:axctazolamideにより強化されるTc-99m ECD SPECTを使用した脳灌かんりゅうリザーブの術前評価
Authors: Tanaka K, Tokui T, Suzuki T, Shimamoto A, Kondo C, Onoda K, Shimono T, Yada I, Matsumura K, Takeda K
Journal: Circulation (2000)
1574P Mortality of 1,636 COVID-19 cancer patients (pts) and associated prognostic factors
Authors: P.A. Ascierto, M.H. Secrest, P. Lambert, K. Sarsour, A. Tan, R. Walls, J. Reddy, A. Seetasith, D. Shenison, I. Ngwa, C. Yun, Q. Zhang
Journal: Annals of Oncology (2021)
High-Density Lipoprotein 3 Cholesterol and Primary Open-Angle Glaucoma
Authors: Simon Nusinovici, Hengtong Li, Sahil Thakur, Mani Baskaran, Yih-Chung Tham, Lei Zhou, Charumathi Sabanayagam, Tin Aung, David Silver, Qiao Fan, Tien Yin Wong, Jonathan Crowston, Ching-Yu Cheng
Journal: Ophthalmology (2021)